摘要
目的探究帕唑帕尼联合放疗对宫颈癌患者血管内皮细胞生长因子受体(vascular endothelial growth factor receptor,VEFGR)水平的影响。方法选取2017年6月-2018年6月于金华市中心医院、浙江省肿瘤医院接受治疗的宫颈癌患者160例,采用随机数字表法分为放疗组、联合组各80例,放疗组进行放射治疗,联合组使用帕唑帕尼联合放射治疗。免疫透射比浊法检测血清癌胚抗原(carcinoembryonic antigen,CEA)、细胞角蛋白19片段抗原(carcinoembryonic antigen,CYFRA21-1)、糖链抗原125(carbohydrate antigen 125,CA125)水平;酶联免疫吸附实验法检测血清VEFGR水平;测定T淋巴细胞亚群水平,对比2组治疗效果及不良反应。结果治疗后,联合组CEA、CYFRA21-1、CA125、CD3^+、CD4^+、VEFGR1、VEFGR2、VEFGR3水平、不良反应发生率均低于放疗组,CD8^+水平、治疗总有效率(85.00%vs. 71.25%)高于放疗组(均P<0.05)。结论帕唑帕尼联合放疗治疗宫颈癌,能够抑制CEA、CYFRA21-1、CA125水平,调控VEFGR水平,治疗效果显著,但二者联用会对机体免疫能力造成影响,因此应进一步分析研究该治疗方案,为该治疗方案的临床应用提供帮助。
Objective To explore the effect of pazopanib combined with radiotherapy on the level of vascular endothelial growth factor receptor(VEFGR) in patients with cervical cancer. Methods From June 2017 to June 2018, 160 patients with cervical cancer who were treated in Jinhua Municipal Central Hospital and Zhejiang Cancer Hospital were randomly divided into radiotherapy group and combination group with 80 cases in each group. Radiotherapy group received radiotherapy and combination group received pazopanib combined radiotherapy. The levels of carcinoembryonic antigen(CEA), cytokeratin 19 fragment antigen(CYFRA21-1), carbohydrate antigen 125(CA125) were detected by immunoturbidimetry;the level of serum VEFGR was detected by enzyme-linked immunosorbent assay;the level of T-lymphocyte subpopulation was measured, and the therapeutic effects and adverse reactions were compared between the two groups. Results After treatment, CEA, CYFRA21-1, CA125, CD3^+, CD4^+, VEFGR1, VEFGR2, VEFGR3 and the incidence of adverse reactions in the combined group were lower than those in the radiotherapy group, CD8^+ and the total effective rate of treatment(85.00% vs. 71.25%) were higher than those in the radiotherapy group(all P<0.05). Conclusion Pazopanil combined with radiotherapy can inhibit CEA, CYFRA21-1 and CA125 levels, regulate VEFGR level, and have a significant therapeutic effect. However, the combination of pazopanib and CA125 will have an impact on the immune capacity of the body. Therefore, further analysis and study of the treatment plan should be carried out to provide help for the clinical application of the treatment plan.
作者
吕红青
张琳
倪镌
LYU Hong-qing;ZHANG Lin;NI Juan(Department of Obstetrics and Gynecology,Jinhua Municipal Central Hospital,Jinhua,Zhejiang 321000,China;不详)
出处
《中华全科医学》
2020年第6期934-937,共4页
Chinese Journal of General Practice
基金
浙江省医药卫生科技计划项目(2020KY056)。
关键词
帕唑帕尼
放疗
宫颈癌
血管内皮细胞生长因子受体
Pazopanib
Radiotherapy
Cervical carcinoma
Vascular endothelial growth factor receptor
